NPS

This page examines the situation with ketamine in Europe. It highlights that ketamine has become an established feature of the drug market in some European countries and that ketamine can be found...

This page examines the situation with new benzodiazepines in Europe. It highlights that new benzodiazepines continue to be used to make fake versions of legitimate medicines and sold on the darknet and...

This page examines the situation with new opioids in Europe. It highlights an increase in reports of nitazene opioid detections and poisonings in parts of Europe and the emergence of mixtures containing...

This page examines the situation with semi-synthetic cannabinoids in Europe. It highlights that these substances appear to be made from naturally occurring cannabinoids, such as CBD, and are sold openly in a...

This page examines the situation with synthetic cannabinoids in Europe. It highlights concerns around low-THC cannabis adulterated with synthetic cannabinoids and edibles containing synthetic cannabinoids. This resource is part of EU Drug...

This page examines the situation with synthetic cathinones in Europe. It highlights a recent sharp increase in the quantity of synthetic cathinones seized in Europe and the growing production of synthetic cathinones...

This page identifies the strategic priority areas that will address the health and security problems associated with the NPS market. This resource is part of EU Drug Markets: In-depth analysis by the...

This page examines the distribution of new psychoactive substances in the European Union. It highlights the number and types of new psychoactive substances on the market in Europe and seizures of new...